Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Long COVID: current status in Japan and knowledge about its molecular background
Akihiro MatsunagaShinya TsuzukiShinichiro MoriokaNorio OhmagariYukihito Ishizaka
著者情報
ジャーナル フリー 早期公開

論文ID: 2022.01013

この記事には本公開記事があります。
詳細
抄録

Even after recovering from coronavirus disease 2019 (COVID-19), patients can experience prolonged complaints, referred to as "long COVID". Similar to reports in Caucasians, a follow-up study in Japan revealed that fatigue, dyspnea, cough, anosmia/dysgeusia, and dyssomnia are common symptoms. Although the precise mode of long COVID remains elusive, multiple etiologies such as direct organ damage by infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), autoimmunity, prolonged inflammatory reactions, and psychiatric impairment seem to be involved. Notably, SARS-CoV-2 is neurotropic, and viral RNA and proteins are continuously detectable in multiple organs, including the brain. Viral proteins exert a number of different toxic effects on cells, suggesting that persistent infection is a key element for understanding long COVID. Here, we first reviewed the current status of long COVID in Japan, and then summarized literature that help us understand the molecular background of the symptoms. Finally, we discuss the feasibility of vaccination as a treatment for patients with long COVID.

著者関連情報
© 2022 National Center for Global Health and Medicine
feedback
Top